How to appeal a Humana compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Cited policy: Humana Compound Medication Policy / Compounded Drug Coverage

Coverage limited to compounded preparations meeting medical necessity, USP compliance, FDA bulks list eligibility; topical pain creams covered when systemic alternatives are contraindicated or have failed.

How Humana denies compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics — and how to counter it

Where Humana pushes back: 1) Topical pain cream not medically necessary; 2) Each component must be FDA-approved for topical use; 3) Bulk powder gabapentin or ketamine alleged not permissible.

Counter-arguments that hold up: For elderly patients or those with renal impairment / GI intolerance to systemic gabapentin, oral NSAID contraindication, or anticoagulation, topical compounded pain cream avoids systemic AEs. Cite individual evidence: gabapentin neuropathic pain (Backonja JAMA 1998 and subsequent), topical lidocaine 5% (FDA-approved patch), topical ketamine analgesia case series, amitriptyline neuropathic pain. Pharmacy compliance documentation. Bulk gabapentin and ketamine HCl are on FDA 503A bulks list Category 1.

What Humana typically denies for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• BHRT compounded
• Bi-Est cream
• Compounded testosterone
• Compounded progesterone
• Low-dose naltrexone (LDN)
• Compounded ketamine

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.